PABLO MINGUEZ GABIÑA-rekin lankidetzan egindako argitalpenak (15)

2023

  1. Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE

    EJNMMI Physics, Vol. 10, Núm. 1

2021

  1. A retrospective study on the potential of 99mTc-HDP imaging before therapy for individualizing treatments with 223Ra-Cl2 for metastatic castration resistant prostate cancer

    Medical Physics, Vol. 48, Núm. 3, pp. 1395-1403

  2. Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer

    Physica Medica, Vol. 88, pp. 45-52

  3. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

2020

  1. Feasibility and limitations of quantitative SPECT for 223Ra

    Physics in Medicine and Biology, Vol. 65, Núm. 8

  2. MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

    Clinical and Translational Radiation Oncology, Vol. 24, pp. 135-139

  3. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial

    Radiotherapy and Oncology, Vol. 146, pp. 16-20

2019

  1. Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively

    Physica Medica, Vol. 65, pp. 143-149

  2. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

    Radiotherapy and Oncology, Vol. 135, pp. 13-18

2018

  1. Comparison of microdosimetry-based absorbed doses to control tumours and clinically obtained tumour absorbed doses in treatments with 223Ra

    Physics in Medicine and Biology, Vol. 63, Núm. 14

  2. Detection and quantification of 223Ra uptake in bone metastases of patients with castration resistant prostate carcinoma, with the aim of determining the absorbed dose in the metastases

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 1, pp. 20-27

  3. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial

    Radiotherapy and Oncology, Vol. 126, Núm. 2, pp. 278-282

2016

  1. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial

    Radiotherapy and Oncology, Vol. 119, Núm. 1, pp. 91-96

  2. Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer

    Medical Physics, Vol. 43, Núm. 10, pp. 5279-5287

2014

  1. Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy

    Journal of Contemporary Brachytherapy, Vol. 6, Núm. 2, pp. 154-160